Bridgeway Capital Management’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Bridgeway Capital Management’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,476	Closed	-$78.8K	–	1446
2022 Q4	$78.8K	Buy	5,476 +3,334	+156%	+$111K	﹤0.01%	1251
2022 Q3	$107K	Buy	2,142 +376	+21%	+$26.1K	﹤0.01%	1257
2022 Q2	$150K	Buy	+1,766	New	+$151K	﹤0.01%	1151

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Bridgeway Capital Management's FNCH Position: Q1 2023 in Review

Bridgeway Capital Management sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q1 2023, closing a stake of 5,476 shares — an estimated $78.8K sold.

Bridgeway Capital Management first reported a position in FNCH in Q2 2022 and held it in 3 quarters. The position peaked at $150K in Q2 2022. 33 funds tracked by Wall St. Rank hold FNCH as of Q1 2023.

Bridgeway Capital Management reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Bridgeway Capital Management sold 5,476 Finch Therapeutics Group, Inc. Common Stock shares in Q1 2023, an estimated $78.8K.
Bridgeway Capital Management first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Bridgeway Capital Management's Finch Therapeutics Group, Inc. Common Stock position peaked at $150K in Q2 2022.
33 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q1 2023.

Based on Bridgeway Capital Management's 13F filing for Q1 2023, filed 15 May 2023.